Table 3.
Factors predictive of HBsAg loss.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Age (per year) | 0.979 (0.953–1.006) | 0.12 | ||
| Sex (Male vs. female) | 2.12 (0.89–5.03) | 0.090 | ||
| Cirrhosis | 1.71 (0.91–3.23) | 0.097 | ||
| FIB-4 | 0.96 (0.88–1.05) | 0.39 | ||
| ETV vs. LAM | 1.01 (0.52–1.98) | 0.97 | ||
| ALT (per ULN) | 1.000 (0.999–1.000) | 0.40 | ||
| Total bilirubin (per mg/dL) | 0.94 (0.87–1.01) | 0.10 | ||
| HBV DNA (per log IU/mL) | 0.97 (0.81–1.17) | 0.77 | ||
| HBV genotype (C vs. B) | 2.46 (1.13–5.37) | 0.024 | 2.55 (1.15–5.62) | 0.021 |
| HBsAg at baseline (per log IU/L) | 0.88 (0.61–1.27) | 0.49 | ||
| HBsAg at month 12 of treatment (per log IU/L) | 0.43 (0.29–0.65) | <0.001 | ||
| HBsAg at the end of treatment (per log IU/L) | 0.34 (0.24–0.49) | <0.001 | 0.33 (0.23–0.47) | <0.001 |
| HBsAg decline from baseline to end of treatment (per log IU/L) | 1.83 (1.34–2.51) | <0.001 | ||
| Treatment duration (per week) | 1.004 (0.999–1.010) | 0.14 | ||
| Consolidation duration (per week) | 1.005 (0.999–1.010) | 0.094 | ||
ALT: alanine aminotransferase, HR: hazard ratio, CI: confidence interval.